中国药物经济学2025，Vol.20Issue(2)：5-9,16,6.DOI:10.12010/j.issn.1673-5846.2025.02.001
司美格鲁肽治疗糖尿病肾病的成本-效用分析
Cost-utility Analysis of Semaglutide in the Treatment of Diabetic Nephropathy
摘要
Abstract
Objective To evaluate the economics of semaglutide in combination with standard therapy for patients with diabetic nephropathy based on a health system perspective.Methods Based on FLOW test data building a Markov model with cycle time of 3 months and simulation time of 20 years for cost-utility analysis.Incremental cost-utility ratios were using to compare to willingness to pay thresholds to evaluate the economics of semaglutide in combination with standard therapy for the treatment of diabetic nephropathy.Sensitivity analysis were used to evaluate the robustness of the results.Results Compared with standard therapy,The incremental cost of adding semaglutide was 60 226.25 yuan,and the incremental utility was 2.12 QALYs.ICUR was 28 356.11 yuan/QALY,less than one times China's GDP per capita in 2023(89 358 yuan).The outcomes of the sensitivity analysis indicate that the findings of this study are robust.Conclusion Compared with standard therapy,semaglutide combined with standard therapy has a cost-utility advantage in the treatment of diabetic nephropathy.关键词
司美格鲁肽/糖尿病肾病/药物经济学/成本-效用分析/Markov模型Key words
Semaglutide/Diabetic nephropathy/Pharmacoeconomics/Cost-utility analysis/Markov model分类
临床医学引用本文复制引用
李嘉豫,寸玉芳,王海秀,邱成省,朱怡璇,魏翼..司美格鲁肽治疗糖尿病肾病的成本-效用分析[J].中国药物经济学,2025,20(2):5-9,16,6.基金项目
大理州科技局备案项目(ZB2024KJ011) （ZB2024KJ011）
